TISIDB

Summary
Symbol	ACTG1
Name	actin gamma 1
Aliases	ACTG; DFNA20; DFNA26; deafness, autosomal dominant 20; deafness, autosomal dominant 26; BRWS2; HEL-176; cyto ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytoskeleton
Domain	PF00022 Actin
Function	Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0001894 tissue homeostasis GO:0001895 retina homeostasis GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002431 Fc receptor mediated stimulatory signaling pathway GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0006909 phagocytosis GO:0007596 blood coagulation GO:0007599 hemostasis GO:0010927 cellular component assembly involved in morphogenesis GO:0030168 platelet activation GO:0030239 myofibril assembly GO:0031032 actomyosin structure organization GO:0034109 homotypic cell-cell adhesion GO:0034329 cell junction assembly GO:0034330 cell junction organization GO:0038093 Fc receptor signaling pathway GO:0038094 Fc-gamma receptor signaling pathway GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis GO:0042692 muscle cell differentiation GO:0045214 sarcomere organization GO:0048010 vascular endothelial growth factor receptor signaling pathway GO:0048013 ephrin receptor signaling pathway GO:0048871 multicellular organismal homeostasis GO:0050817 coagulation GO:0050878 regulation of body fluid levels GO:0051146 striated muscle cell differentiation GO:0055001 muscle cell development GO:0055002 striated muscle cell development GO:0060249 anatomical structure homeostasis GO:0070527 platelet aggregation
Molecular Function	GO:0005200 structural constituent of cytoskeleton GO:0031625 ubiquitin protein ligase binding GO:0044389 ubiquitin-like protein ligase binding
Cellular Component	GO:0005884 actin filament GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0015629 actin cytoskeleton GO:0030016 myofibril GO:0030055 cell-substrate junction GO:0031941 filamentous actin GO:0043209 myelin sheath GO:0043292 contractile fiber GO:0072562 blood microparticle GO:0097433 dense body

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04015 Rap1 signaling pathway hsa04145 Phagosome hsa04210 Apoptosis hsa04390 Hippo signaling pathway hsa04510 Focal adhesion hsa04520 Adherens junction hsa04530 Tight junction hsa04611 Platelet activation hsa04670 Leukocyte transendothelial migration hsa04810 Regulation of actin cytoskeleton hsa04919 Thyroid hormone signaling pathway hsa04921 Oxytocin signaling pathway
Reactome	R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-2682334: EPH-Ephrin signaling R-HSA-3928662: EPHB-mediated forward signaling R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-195258: RHO GTPase Effectors R-HSA-5663220: RHO GTPases Activate Formins R-HSA-5663213: RHO GTPases Activate WASPs and WAVEs R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04015 Rap1 signaling pathway
hsa04145 Phagosome
hsa04210 Apoptosis
hsa04390 Hippo signaling pathway
hsa04510 Focal adhesion
hsa04520 Adherens junction
hsa04530 Tight junction
hsa04611 Platelet activation
hsa04670 Leukocyte transendothelial migration
hsa04810 Regulation of actin cytoskeleton
hsa04919 Thyroid hormone signaling pathway
hsa04921 Oxytocin signaling pathway

Reactome

R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928662: EPHB-mediated forward signaling
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663220: RHO GTPases Activate Formins
R-HSA-5663213: RHO GTPases Activate WASPs and WAVEs
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases

Summary
Symbol	ACTG1
Name	actin gamma 1
Aliases	ACTG; DFNA20; DFNA26; deafness, autosomal dominant 20; deafness, autosomal dominant 26; BRWS2; HEL-176; cyto ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ACTG1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ACTG1
Name	actin gamma 1
Aliases	ACTG; DFNA20; DFNA26; deafness, autosomal dominant 20; deafness, autosomal dominant 26; BRWS2; HEL-176; cyto ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ACTG1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.82	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ACTG1
Name	actin gamma 1
Aliases	ACTG; DFNA20; DFNA26; deafness, autosomal dominant 20; deafness, autosomal dominant 26; BRWS2; HEL-176; cyto ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ACTG1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.281	0.425
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.47	0.926
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.145	0.968
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.158	0.783
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.207	0.951
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.631	0.891
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.025	0.971
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.243	0.938
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.283	0.936
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.326	0.922
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.592	0.908
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.133	0.021

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ACTG1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	16.7	-4.2	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	100	-100	0.143
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ACTG1
Name	actin gamma 1
Aliases	ACTG; DFNA20; DFNA26; deafness, autosomal dominant 20; deafness, autosomal dominant 26; BRWS2; HEL-176; cyto ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACTG1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ACTG1
Name	actin gamma 1
Aliases	ACTG; DFNA20; DFNA26; deafness, autosomal dominant 20; deafness, autosomal dominant 26; BRWS2; HEL-176; cyto ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACTG1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACTG1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ACTG1
Name	actin gamma 1
Aliases	ACTG; DFNA20; DFNA26; deafness, autosomal dominant 20; deafness, autosomal dominant 26; BRWS2; HEL-176; cyto ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACTG1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ACTG1
Name	actin gamma 1
Aliases	ACTG; DFNA20; DFNA26; deafness, autosomal dominant 20; deafness, autosomal dominant 26; BRWS2; HEL-176; cyto ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ACTG1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ACTG1
Name	actin gamma 1
Aliases	ACTG; DFNA20; DFNA26; deafness, autosomal dominant 20; deafness, autosomal dominant 26; BRWS2; HEL-176; cyto ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ACTG1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ACTG1
Name	actin gamma 1
Aliases	ACTG; DFNA20; DFNA26; deafness, autosomal dominant 20; deafness, autosomal dominant 26; BRWS2; HEL-176; cyto ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ACTG1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ACTG1.

ID	Name	Drug Type	Targets	#Targets
DB09130	Copper	Small Molecule	A1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......	141
DB11638	Artenimol	Small Molecule	ACTG1, ALB, ALDH7A1, ALDOA, ANXA2, ATP5A1, ATP5L, ATP5O, CAST, CCT ......	79

Browse ACTG1